April 1, 2022
April 1, 2022 – Gilead’s Yescarta® (axicabtagene ciloleucel) has been approved to treat adults diagnosed
with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health
April 1, 2022
April 1, 2022 – ViiV Healthcare’s Triumeq PD® (abacavir/dolutegravir/lamivudine) has been approved to
treat HIV-1 infection in children who weigh 10kg (22 pounds) to less than 25kg (55 pounds)
March 30, 2022
March 30, 2022 – Janssen’s Edurant® (rilpivirine) and ViiV Healthcare’s Vocabria® (cabotegravir) have
received expanded indications for the short-term treatment of HIV-1 infection
March 30, 2022
March 30, 2022 – The FDA has approved updated prescribing information for Cabenuva® (cabotegravir and rilpivirine), ViiV Healthcare’s long-lasting injectable HIV treatment
March 29, 2022
March 29, 2022 – The U.S. FDA has approved higher Ozempic® (semaglutide) dosing to improve glycemic control in adults who have type 2 diabetes. Ozempic, which previously
March 29, 2022
March 29, 2022 – Both Pfizer and Moderna have received emergency use authorization (EUA) for a second
booster dose of their COVID-19 vaccines in certain populations. For both products
March 29, 2022
March 29, 2022 – The FDA has approved TlandoTM (testosterone undecanoate), made by Antares Pharma, for testosterone replacement therapy (TRT). Tlando is the first oral TRT
March 28, 2022
March 28, 2022 – UCB’s Fintepla® (fenfluramine) has obtained an expanded indication to treat seizures
associated with Dravet syndrome and Lennox-Gastaut syndrome in patients at